A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs ASP 8062 (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 Planned initiation date changed from 17 Apr 2017 to 31 May 2017.
- 14 Feb 2017 New trial record